Rimfire Pacific Mining has appointed Bronwyn Barnes as Executive Chair and secured $2.3 million in a placement to advance its scandium exploration and development strategy.
- Bronwyn Barnes named Executive Chair from September 2026
- Placement raises $2.3 million at 0.8 cents per share
- Directors and management invest $580K in placement
- Board renewal with Ian McCubbing and David Hutton shifting roles
- Funds earmarked for metallurgical studies, drilling, and working capital
Leadership Overhaul to Drive Scandium Ambitions
Rimfire Pacific Mining (ASX:RIM) is recalibrating its leadership and funding to sharpen its focus on scandium, a critical mineral gaining traction in advanced manufacturing and aerospace sectors. The appointment of Bronwyn Barnes as Executive Chair, effective 1 September 2026, signals a strategic pivot to accelerate the company’s development phase.
Ms Barnes brings over 30 years of mining sector experience, including executive roles and board positions across ASX-listed and international companies. Her expertise in project development, corporate finance, and government engagement is expected to bolster Rimfire’s pathway from resource definition to commercial execution. Meanwhile, current Chair Ian McCubbing will transition to a Non-Executive Director role, and Managing Director David Hutton will become Technical Director, focusing on exploration and resource growth.
Capital Raising Backs Scandium Strategy with Strong Insider Support
Backing this leadership refresh, Rimfire has secured $2.3 million through a placement priced at 0.8 cents per share, representing a 27% discount to recent trading prices. The raise attracted firm commitments from professional and sophisticated investors, including $580,000 from directors and management, underscoring strong internal confidence in Rimfire’s scandium ambitions.
The placement shares will be issued in two tranches, with the second tranche, including Ms Barnes’ participation, subject to shareholder approval at a general meeting scheduled for September 2026. Additionally, free attaching unlisted options exercisable at 1.5 cents each are to be issued on a one-for-one basis, also awaiting shareholder consent.
Funding to Accelerate Technical and Drilling Programs
Proceeds from the placement will fund expanded drilling programs, metallurgical studies, and general working capital. Rimfire is particularly focused on advancing its low-iron scandium processing methodologies and accelerating resource expansion to support future development and feasibility studies.
This technical push aligns with the company’s broader strategy to capitalise on growing global demand for scandium, driven by sectors such as AI data centres, defence, aerospace, and clean energy technologies. The refreshed leadership and capital injection position Rimfire to enhance its standing as a leading Australian pure-play scandium developer.
Equity Incentives Aim to Align Executive Interests
Ms Barnes’ remuneration package includes a fixed annual salary of $250,000 and performance rights totalling up to 165 million, subject to shareholder approval. These rights vest based on share price milestones and the commencement of a fully funded feasibility study for the Fifield Earn In project, expiring in late 2029. Additionally, 20 million unlisted incentive options exercisable at 1.5 cents will be granted, further aligning executive incentives with shareholder returns.
While these incentives are conditional on shareholder approval, they reflect the board’s commitment to disciplined execution and long-term value creation amid a critical phase of growth.
Bottom Line?
Rimfire’s leadership renewal and $2.3 million capital raise set the stage for a decisive push into scandium development, with shareholder approval looming as the next key hurdle.
Questions in the middle?
- Will shareholder approval for the tranche 2 placement and equity incentives pass smoothly?
- How will metallurgical study outcomes influence the economics of Rimfire’s scandium projects?
- Can the new leadership secure strategic partnerships to accelerate commercialisation?